The impressive impact of cisplatin on cancer on one side and severe side effects, as well as the development of drug resistance during treatment on the other side, were the factors motivating scientists to design and synthesize new more potent analogues lacking disadvantages of cisplatin. Platinum(IV) complexes represent one of the perspective groups of platinum-based drugs. In this review, we summarize recent findings on both in vitro and in vivo effects of platinum(IV) complexes with adamantylamine. Based on a literary overview of the mechanisms of activity of platinum-based cytostatics, we discuss opportunities for modulating the effects of novel platinum complexes through interactions with apoptotic signaling pathways and with cellular lipids, including modulations of the mitochondrial cell death pathway, oxidative stress, signaling of death ligands, lipid metabolism/signaling, or intercellular communication. These approaches might significantly enhance the efficacy of both novel and established platinum-based cytostatics.

Department of Cytokinetics Institute of Biophysics Královopolská 135 612 65 Brno Czech Republic

Zobrazit více v PubMed

Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Annals of Internal Medicine. 1984;100(5): 704–713. PubMed

Brabec V, Kasparkova J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resistance Updates. 2005;8(3):131–146. PubMed

Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery. 2005;4(4):307–320. PubMed

Hartmann JT, Lipp H-P. Toxicity of platinum compounds. Expert Opinion on Pharmacotherapy. 2003;4(6):889–901. PubMed

Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Seminars in Oncology. 1999;26(6):647–662. PubMed

O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs. 2000;59(supplement 4):19–27. PubMed

Lippert B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Weinheim, Germany: Wiley-VCH; 1999.

Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review) Oncology Reports. 2004;11(3):559–595. PubMed

Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clinical Cancer Research. 2001;7(9):2611–2619. PubMed

Norman HA, Butrum RR, Feldman E, et al. The role of dietary supplements during cancer therapy. Journal of Nutrition. 2003;133(11) supplement 1:3794–3799. PubMed

Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. British Journal of Cancer. 1993;67(4):728–733. PubMed PMC

Sagar PS, Das UN. Gamma-linolenic acid and eicosapentaeonic acid potentiate the cytotoxicity of anti-cancer drugs on human cervical carcinoma (HeLa) cells in vitro. Medical Science Research. 1993;21(12):457–459.

Sasaki H, Fukushima M. Prostaglandins in the treatment of cancer. Anti-Cancer Drugs. 1994;5(2):131–138. PubMed

Sam TSW, Ngan MP, Riendeau D, Robichaud A, Rudd JA. Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret. Journal of Pharmacological Sciences. 2007;103(2):189–200. PubMed

Žák F, Turánek J, Kroutil A, et al. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. Journal of Medicinal Chemistry. 2004;47(3):761–763. PubMed

Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–699. PubMed

Giandomenico CM, Abrams MJ, Murrer BA, et al. Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entrée orally-active platinum(IV) antitumor agents. Inorganic Chemistry. 1995;34(5):1015–1021. PubMed

Talman EG, Kidani Y, Mohrmann L, Reedijk J. Can Pt(IV)-amine complexes act as “prodrugs”? Inorganica Chimica Acta. 1998;283(1):251–255.

Wong E, Giandornenico CM. Current status of platinum-based antitumor drugs. Chemical Reviews. 1999;99(9):2451–2466. PubMed

Cermanova J, Chladek J, Soval P, et al. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]-amminedichloroplatinum [IV]) in pigs. Methods and Findings in Experimental and Clinical Pharmacology. 2004;26(9):679–685. PubMed

Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anti-Cancer Drugs. 2005;16(6):653–657. PubMed

Kozubík A, Horváth V, Švihálková-Šindlerová L, et al. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochemical Pharmacology. 2005;69(3):373–383. PubMed

Turánek J, Kašná A, Záluská D, et al. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anti-Cancer Drugs. 2004;15(5):537–543. PubMed

Procházka L, Turánek J, Tesařík R, et al. Apoptosis and inhibition of gap-junctional intercellular communication induced by LA-12, a novel hydrophobic platinum(IV) complex. Archives of Biochemistry and Biophysics. 2007;462(1):54–61. PubMed

Horváth V, Blanářová O, Švihálková-Šindlerová L, et al. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecologic Oncology. 2006;102(1):32–40. PubMed

Kašpárková J, Nováková O, Vrána O, Intini F, Natile G, Brabec V. Molecular aspects of antitumor effects of a new platinum(IV) drug. Molecular Pharmacology. 2006;70(5):1708–1719. PubMed

Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Progress in Nucleic Acid Research and Molecular Biology. 2001;67:93–130. PubMed

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–7279. PubMed

Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chemical Reviews. 1999;99(9):2467–2498. PubMed

Brouwer J, Van De Putte P, Fichtinger-Schepman AM, Reedijk J. Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II) Proceedings of the National Academy of Sciences of the United States of America. 1981;78(11):7010–7014. PubMed PMC

Fuertesa MA, Castillab J, Alonsoa C, Perez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Current Medicinal Chemistry. 2003;10(3):257–266. PubMed

Perez RP. Cellular and molecular determinants of cisplatin resistance. European Journal of Cancer. 1998;34(10):1535–1542. PubMed

Moeller N, Kangarloo BS, Puscasu I, Mock C, Krebs B, Wolff JEA. Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity. Anticancer Research. 2000;20(6 B):4435–4439. PubMed

Kool M, De Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Research. 1997;57(16):3537–3547. PubMed

Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochemical Pharmacology. 2000;60(9):1305–1313. PubMed

Kelland LR. Structure-activity relationship within di- and trinuclear platinum phase I clinical agents. In: Lippert B, editor. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Weinheim, Germany: Wiley-VCH; 1999. pp. 497–521.

Hendrich AB, Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Current Drug Targets. 2003;4(1):23–30. PubMed

Gouaze-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochimica et Biophysica Acta. 2006;1758(12):2096–2103. PubMed

Hinrichs JWJ, Klappe K, Kok JW. Rafts as missing link between multidrug resistance and sphingolipid metabolism. Journal of Membrane Biology. 2005;203(2):57–64. PubMed

Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anti-Cancer Agents in Medicinal Chemistry. 2007;7(1):3–18. PubMed

Tardito S, Bussolati O, Gaccioli F, et al. Non-apoptotic programmed cell death induced by a copper(II) complex in human fibrosarcoma cells. Histochemistry and Cell Biology. 2006;126(4):473–482. PubMed

Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene. 2001;20(17):2122–2133. PubMed

Rodriguez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Current Pharmaceutical Design. 2006;12(34):4411–4425. PubMed

Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochemical and Biophysical Research Communications. 2005;331(3):859–867. PubMed

Debatin K-M, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004;23(16):2950–2966. PubMed

Vaculová A, Hofmanová J, Anděra L, Kozubík A. TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death. Cancer Letters. 2005;229(1):43–48. PubMed

Vaculová A, Hofmanová J, Souček K, Kozubík A. Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Letters. 2006;580(28–29):6565–6569. PubMed

Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate. 2005;62(2):165–186. PubMed

Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel M-T. Sensitization of cancer cells treated with cytotoxic drugs to fas- mediated cytotoxicity. Journal of the National Cancer Institute. 1997;89(11):783–789. PubMed

Delmas D, Rébé C, Micheau O, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene. 2004;23(55):8979–8986. PubMed

Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel M-T. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Research. 2001;61(4):1645–1651. PubMed

Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Kishi M, Konishi N. Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis. 2004;25(7):1089–1097. PubMed

Kinoshita H, Yoshikawa H, Shiiki K, Hamada Y, Nakajima Y, Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. International Journal of Cancer. 2000;88(6):986–991. PubMed

Liu W, Bodle E, Che JY, Gao M, Rosen GD, Broaddus VC. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. American Journal of Respiratory Cell and Molecular Biology. 2001;25(1):111–118. PubMed

Tsai WS, Yeow W-S, Chua A, et al. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Molecular Cancer Therapeutics. 2006;5(12):2977–2990. PubMed

Nguyen DM, Yeow W-S, Firdos Ziauddin M, et al. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death. Cancer Journal. 2006;12(4):257–273. PubMed

Wang P, Song JH, Song DK, Zhang J, Hao C. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cellular Signalling. 2006;18(9):1528–1535. PubMed

Rosen M, Figliomeni M, Simpkins H. The interaction of platinum antitumour drugs with mouse liver mitochondria. International Journal of Experimental Pathology. 1992;73(1):61–74. PubMed PMC

Zhang L, Cooper AJL, Krasnikov BF, et al. Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the α-ketoglutarate dehydrogenase complex in LLC-PK1 cells. Biochemistry. 2006;45(29):8959–8971. PubMed PMC

Souid A-K, Tacka KA, Galvan KA, Penefsky HS. Immediate effects of anticancer drugs on mitochondrial oxygen consumption. Biochemical Pharmacology. 2003;66(6):977–987. PubMed

Evans RM, Simpkins H. Cisplatin induced intermediate filament reorganization and altered mitochondrial function in 3T3 cells and drug-sensitive and -resistant walker 256 cells. Experimental Cell Research. 1998;245(1):69–78. PubMed

Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clinical Cancer Research. 2006;12(19):5817–5825. PubMed

Dong Y, Berners-Price SJ, Thorburn DR, et al. Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy. Biochemical Pharmacology. 1997;53(11):1673–1682. PubMed

Qian W, Nishikawa M, Haque AM, et al. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. American Journal of Physiology—Cell Physiology. 2005;289(6):C1466–C1475. PubMed

Isonishi S, Saitou M, Yasuda M, Tanaka T. Mitochondria in platinum resistant cells. Human Cell. 2001;14(3):203–210. PubMed

Endo K, Kohnoe S, Tsujita E, et al. Modulation of anti-apoptosis by endogenous IAP expression in MKN45 human gastric cancer cells. Anticancer Research. 2005;25(4):2713–2718. PubMed

Cho HJ, Kim JK, Kim KD, et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Letters. 2006;237(1):56–66. PubMed

Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer. 2004;91(11):1931–1946. PubMed PMC

Mueller T, Voigt W, Simon H, et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Research. 2003;63(2):513–521. PubMed

Ding Z, Yang X, Pater A, Tang S-C. Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells. Biochemical and Biophysical Research Communications. 2000;270(2):415–420. PubMed

Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. Journal of Biological Chemistry. 2005;280(35):31230–31239. PubMed

Francescato HDC, Costa RS, Scavone C, Coimbra TM. Parthenolide reduces cisplatin-induced renal damage. Toxicology. 2007;230(1):64–75. PubMed

Drewa T, Woźniak A, Drewa G, et al. Effect of novel platinum complexes on survival rate of B16 and Cl S91 melanoma cells and oxidation stress in vitro. Medical Science Monitor. 2001;7(4):680–686. PubMed

Sentürker S, Tschirret-Guth R, Morrow J, Levine R, Shacter E. Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Archives of Biochemistry and Biophysics. 2002;397(2):262–272. PubMed

Kaludjerović GN, Miljković D, Momcilović M, et al. Novel platinum(IV) complexes induce rapid tumor cell death in vitro. International Journal of Cancer. 2005;116(3):479–486. PubMed

Husain K, Whitworth C, Rybak LP. Time response of carboplatin-induced nephrotoxicity in rats. Pharmacological Research. 2004;50(3):291–300. PubMed

Olas B, Wachowicz B, Majsterek I, Blasiak J. Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes. Anti-Cancer Drugs. 2005;16(6):659–665. PubMed

Pogrebniak HW, Prewitt TW, Matthews WA, Pass HI. Tumor necrosis factor-α alters response of lung cancer cells to oxidative stress. Journal of Thoracic and Cardiovascular Surgery. 1991;102(6):904–907. PubMed

Escribá PV. Membrane-lipid therapy: a new approach in molecular medicine. Trends in Molecular Medicine. 2006;12(1):34–43. PubMed

Brown MD, Hart CA, Gazi E, Bagley S, Clarke NW. Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. British Journal of Cancer. 2006;94(6):842–853. PubMed PMC

Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis. 1999;20(12):2209–2218. PubMed

Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacology and Therapeutics. 1999;83(3):217–244. PubMed

Davidson LA, Nguyen DV, Hokanson RM, et al. Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Research. 2004;64(18):6797–6804. PubMed PMC

Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. American Journal of Clinical Nutrition. 2004;79(6):935–945. PubMed

Hardman WE, Avula CP, Fernandes G, Cameron IL. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clinical Cancer Research. 2001;7(7):2041–2049. PubMed

Jordan A, Stein J. Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. European Journal of Nutrition. 2003;42(6):324–331. PubMed

Bougnoux P, Germain E, Chajés V, et al. Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. British Journal of Cancer. 1999;79(11-12):1765–1769. PubMed PMC

Timmer-Bosscha H, Hospers GAP, Meijer C, et al. Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. Journal of the National Cancer Institute. 1989;81(14):1069–1075. PubMed

Yam D, Peled A, Shinitzky M. Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemotherapy and Pharmacology. 2001;47(1):34–40. PubMed

Jho DH, Cole SM, Lee EM, Espat NJ. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integrative Cancer Therapies. 2004;3(2):98–111. PubMed

Escriba PV, Ferrer-Montiel AV, Ferragut JA, Gonzalez-Ros JM. Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochemistry. 1990;29(31):7275–7282. PubMed

Mikirova N, Riordan HD, Jackson JA, Wong K, Miranda-Massari JR, Gonzalez MJ. Erythrocyte membrane fatty acid composition in cancer patients. Puerto Rico Health Sciences Journal. 2004;23(2):107–113. PubMed

Liang X-J, Yin J-J, Zhou J-W, et al. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Experimental Cell Research. 2004;293(2):283–291. PubMed

Mann SC, Andrews PA, Howell SB. Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Research. 1988;8(6):1211–1215. PubMed

Liu Q, Qu Y, Van Antwerpen R, Farrell N. Mechanism of the membrane interaction of polynuclear platinum anticancer agents. Implications for cellular uptake. Biochemistry. 2006;45(13):4248–4256. PubMed

Speelmans G, Staffhorst RWHM, Versluis K, Reedijk J, De Kruijff B. Cisplatin complexes with phosphatidylserine in membranes. Biochemistry. 1997;36(34):10545–10550. PubMed

Das U. A radical approach to cancer. Medical Science Monitor. 2002;8(4):RA79–RA92. PubMed

Meydani SN. Effect of (n-3) polyunsaturated fatty acids on cytokine production and their biologic function. Nutrition. 1996;12(1) supplement:8–14. PubMed

Rudolph IL, Kelley DS, Klasing KC, Erickson KL. Regulation of cellular differentiation and apoptosis by fatty acids and their metabolites. Nutrition Research. 2001;21(1-2):381–393. PubMed

Los DA, Murata N. Membrane fluidity and its roles in the perception of environmental signals. Biochimica et Biophysica Acta. 2004;1666(1-2):142–157. PubMed

Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Research. 2004;64(10):3593–3598. PubMed

Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chemistry and Physics of Lipids. 2003;126(1):1–27. PubMed

Pohl J, Ring A, Ehehalt R, Herrmann T, Stremmel W. New concepts of cellular fatty acid uptake: role of fatty acid transport proteins and of caveolae. Proceedings of the Nutrition Society. 2004;63(2):259–262. PubMed

Krönke M. Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes. Chemistry and Physics of Lipids. 1999;101(1):109–121. PubMed

Schley PD, Brindley DN, Field CJ. (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. Journal of Nutrition. 2007;137(3):548–553. PubMed

Fernández-Checa JC. Redox regulation and signaling lipids in mitochondrial apoptosis. Biochemical and Biophysical Research Communications. 2003;304(3):471–479. PubMed

Hirunpanich V, Katagi J, Sethabouppha B, Sato H. Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. Drug Metabolism and Disposition. 2006;34(2):305–310. PubMed

Liu QY, Tan BKH. Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sciences. 2000;67(10):1207–1218. PubMed

Abulrob AN, Mason M, Bryce R, Gumbleton M. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance. Journal of Drug Targeting. 2000;8(4):247–256. PubMed

Di Paola M, Lorusso M. Interaction of free fatty acids with mitochondria: coupling, uncoupling and permeability transition. Biochimica et Biophysica Acta. 2006;1757(9-10):1330–1337. PubMed

Kagan VE, Borisenko GG, Tyurina YY, et al. Oxidative lipidomics of apoptosis: redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine. Free Radical Biology and Medicine. 2004;37(12):1963–1985. PubMed

Ng Y, Barhoumi R, Tjalkens RB, et al. The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis. 2005;26(11):1914–1921. PubMed PMC

Degli Esposti M, Ferry G, Masdehors P, Boutin JA, Hickman JA, Dive C. Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3. Journal of Biological Chemistry. 2003;278(18):15749–15757. PubMed

Maziére C, Conte M-A, Degonville J, Ali D, Maziére J-C. Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFκB. Biochemical and Biophysical Research Communications. 1999;265(1):116–122. PubMed

Hofmanová J, Vaculová A, Kozubík A. Polyunsaturated fatty acids sensitize human colon adenocarcinoma HT-29 cells to death receptor-mediated apoptosis. Cancer Letters. 2005;218(1):33–41. PubMed

Muzio G, Salvo RA, Trombetta A, et al. Dose-dependent inhibition of cell proliferation induced by lipid peroxidation products in rat hepatoma cells after enrichment with arachidonic acid. Lipids. 1999;34(7):705–711. PubMed

Das UN, Huang YS, Begin ME, Ells G, Horrobin DF. Uptake and distribution of cis-unsaturated fatty acids and their effect on free radical generation in normal and tumor cells in vitro. Free Radical Biology & Medicine. 1987;3(1):9–14. PubMed

Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radical Biology and Medicine. 2007;42(2):153–164. PubMed

Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxidants and Redox Signaling. 2005;7(3-4):395–403. PubMed

Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annual Review of Nutrition. 2005;25:317–340. PubMed

Mills SC, Windsor AC, Knight SC. The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes. Clinical and Experimental Immunology. 2005;142(2):216–228. PubMed PMC

Yusufi ANK, Cheng J, Thompson MA, et al. Differential effects of low-dose docosahexaenoic acid and eicosapentaenoic acid on the regulation of mitogenic signaling pathways in mesangial cells. Journal of Laboratory and Clinical Medicine. 2003;141(5):318–329. PubMed

Yang W-L, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001;22(9):1379–1383. PubMed

Diggle CP. In vitro studies on the relationship between polyunsaturated fatty acids and cancer: tumour or tissue specific effects? Progress in Lipid Research. 2002;41(3):240–253. PubMed

Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomedicine and Pharmacotherapy. 2002;56(8):365–379. PubMed

Toriyama-Baba H, Iigo M, Asamoto M, et al. Organotropic chemopreventive effects of n-3 unsaturated fatty acids in a rat multi-organ carcinogenesis model. Japanese Journal of Cancer Research. 2001;92(11):1175–1183. PubMed PMC

Dentin R, Benhamed F, Pégorier J-P, et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. Journal of Clinical Investigation. 2005;115(10):2843–2854. PubMed PMC

Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Medicinal chemistry. 2005;1(2):125–139. PubMed

Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clinical Cancer Research. 2001;7(10):3229–3238. PubMed

Kuznetsova L, Chen J, Sun L, et al. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorganic and Medicinal Chemistry Letters. 2006;16(4):974–977. PubMed

Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Advanced Drug Delivery Reviews. 1999;40(1-2):75–87. PubMed

Working PK, Newman MS, Sullivan T, et al. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicological Sciences. 1998;46(1):155–165. PubMed

Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Research. 2005;25(4):3031–3040. PubMed

Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Research. 2006;26(2 B):1489–1493. PubMed

Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 2006;58(6):759–764. PubMed

Mesnil M, Crespin S, Avanzo J-L, Zaidan-Dagli M-L. Defective gap junctional intercellular communication in the carcinogenic process. Biochimica et Biophysica Acta. 2005;1719(1-2):125–145. PubMed

Trosko JE, Chang C-C. Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer. Mutation Research. 2001;480-481:219–229. PubMed

Giessmann D, Theiss C, Breipohl W, Meller K. Decreased gap junctional communication in neurobiotin microinjected lens epithelial cells after taxol treatment. Anatomy and Embryology. 2005;209(5):391–400. PubMed

Abdelmohsen K, von Montfort C, Stuhlmann D, et al. Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells. Biological Chemistry. 2005;386(3):217–223. PubMed

Zhao W, Lin ZX, Zhang ZQ. Cisplatin-induced premature senescence with concomitant reduction of gap junctions in human fibroblasts. Cell Research. 2004;14(1):60–66. PubMed

Presley CA, Lee AW, Kastl B, et al. Bone marrow connexin-43 expression is critical for hematopoietic regeneration after chemotherapy. Cell Communication and Adhesion. 2005;12(5-6):307–317. PubMed

Carystinos GD, Alaoui-Jamali MA, Phipps J, Yen L, Batist G. Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells. Cancer Chemotherapy and Pharmacology. 2001;47(2):126–132. PubMed

Tanaka M, Grossman HB. Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncology Reports. 2004;11(2):537–541. PubMed

Toler CR, Taylor DD, Gercel-Taylor C. Loss of communication in ovarian cancer. American Journal of Obstetrics and Gynecology. 2006;194(5):e27–e31. PubMed

Kawamura K, Bahar R, Namba H, et al. Bystander effect in uracil phosphoribosyltransferase/5-fluorouracil-mediated suicide gene therapy is correlated with the level of intercellular communication. International Journal of Oncology. 2001;18(1):117–120. PubMed

Edwards GO, Botchway SW, Hirst G, Wharton CW, Chipman JK, Meldrum RA. Gap junction communication dynamics and bystander effects from ultrasoft X-rays. British Journal of Cancer. 2004;90(7):1450–1456. PubMed PMC

Jensen R, Glazer PM. Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(16):6134–6139. PubMed PMC

Bunz F. Cell death and cancer therapy. Current Opinion in Pharmacology. 2001;1(4):337–341. PubMed

Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resistance Updates. 2004;7(4-5):227–232. PubMed

Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells

Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells

The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo

The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin